157 related articles for article (PubMed ID: 29035381)
1. High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models.
Quagliata L; Quintavalle C; Lanzafame M; Matter MS; Novello C; di Tommaso L; Pressiani T; Rimassa L; Tornillo L; Roncalli M; Cillo C; Pallante P; Piscuoglio S; Ng CK; Terracciano LM
Lab Invest; 2018 Jan; 98(1):95-105. PubMed ID: 29035381
[TBL] [Abstract][Full Text] [Related]
2. Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients.
Quagliata L; Matter MS; Piscuoglio S; Arabi L; Ruiz C; Procino A; Kovac M; Moretti F; Makowska Z; Boldanova T; Andersen JB; Hämmerle M; Tornillo L; Heim MH; Diederichs S; Cillo C; Terracciano LM
Hepatology; 2014 Mar; 59(3):911-23. PubMed ID: 24114970
[TBL] [Abstract][Full Text] [Related]
3. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
4. MiR-369-5p inhibits the proliferation and migration of hepatocellular carcinoma cells by down-regulating HOXA13 expression.
Qian X; Wang Y; Hu W; Xu X; Gao L; Meng Y; Yan J
Tissue Cell; 2022 Feb; 74():101721. PubMed ID: 34979376
[TBL] [Abstract][Full Text] [Related]
5. The HOX gene network in hepatocellular carcinoma.
Cillo C; Schiavo G; Cantile M; Bihl MP; Sorrentino P; Carafa V; D' Armiento M; Roncalli M; Sansano S; Vecchione R; Tornillo L; Mori L; De Libero G; Zucman-Rossi J; Terracciano L
Int J Cancer; 2011 Dec; 129(11):2577-87. PubMed ID: 21626505
[TBL] [Abstract][Full Text] [Related]
6. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
Wang M; Wang Z; Zhi X; Ding W; Xiong J; Tao T; Yang Y; Zhang H; Zi X; Zhou W; Huang G
Biomed Pharmacother; 2020 Sep; 129():110315. PubMed ID: 32554246
[TBL] [Abstract][Full Text] [Related]
7. Long Noncoding RNA (lncRNA) Small Nucleolar RNA Host Gene 16 (SNHG16) Predicts Poor Prognosis and Sorafenib Resistance in Hepatocellular Carcinoma.
Guo Z; Zhang J; Fan L; Liu J; Yu H; Li X; Sun G
Med Sci Monit; 2019 Mar; 25():2079-2086. PubMed ID: 30893293
[TBL] [Abstract][Full Text] [Related]
8. MiR-30e-3p Influences Tumor Phenotype through
Gramantieri L; Pollutri D; Gagliardi M; Giovannini C; Quarta S; Ferracin M; Casadei-Gardini A; Callegari E; De Carolis S; Marinelli S; Benevento F; Vasuri F; Ravaioli M; Cescon M; Piscaglia F; Negrini M; Bolondi L; Fornari F
Cancer Res; 2020 Apr; 80(8):1720-1734. PubMed ID: 32015093
[TBL] [Abstract][Full Text] [Related]
9. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer.
Li Z; Zhao X; Zhou Y; Liu Y; Zhou Q; Ye H; Wang Y; Zeng J; Song Y; Gao W; Zheng S; Zhuang B; Chen H; Li W; Li H; Li H; Fu Z; Chen R
J Transl Med; 2015 Mar; 13():84. PubMed ID: 25889214
[TBL] [Abstract][Full Text] [Related]
10. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m
Chen YT; Xiang D; Zhao XY; Chu XY
Hum Cell; 2021 Nov; 34(6):1800-1811. PubMed ID: 34374933
[TBL] [Abstract][Full Text] [Related]
12. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
[TBL] [Abstract][Full Text] [Related]
13. m6A RNA methylation-mediated HNF3γ reduction renders hepatocellular carcinoma dedifferentiation and sorafenib resistance.
Zhou T; Li S; Xiang D; Liu J; Sun W; Cui X; Ning B; Li X; Cheng Z; Jiang W; Zhang C; Liang X; Li L; Cheng X; Hui L; Wang H; Ding J
Signal Transduct Target Ther; 2020 Dec; 5(1):296. PubMed ID: 33361765
[TBL] [Abstract][Full Text] [Related]
14. Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma.
Fan L; Huang X; Chen J; Zhang K; Gu YH; Sun J; Cui SY
Mol Cancer Ther; 2020 May; 19(5):1197-1209. PubMed ID: 32220970
[TBL] [Abstract][Full Text] [Related]
15. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
Wu J; Chai H; Li F; Ren Q; Gu Y
Life Sci; 2020 Nov; 260():118406. PubMed ID: 32918976
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
17. Cirrhotic stiffness affects the migration of hepatocellular carcinoma cells and induces sorafenib resistance through YAP.
Gao J; Rong Y; Huang Y; Shi P; Wang X; Meng X; Dong J; Wu C
J Cell Physiol; 2019 Mar; 234(3):2639-2648. PubMed ID: 30145835
[TBL] [Abstract][Full Text] [Related]
18. LncRNA FOXD2-AS1 as a competitive endogenous RNA against miR-150-5p reverses resistance to sorafenib in hepatocellular carcinoma.
Sui C; Dong Z; Yang C; Zhang M; Dai B; Geng L; Lu J; Yang J; Xu M
J Cell Mol Med; 2019 Sep; 23(9):6024-6033. PubMed ID: 31210410
[TBL] [Abstract][Full Text] [Related]
19. EPHB2 Activates β-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma.
Leung HW; Leung CON; Lau EY; Chung KPS; Mok EH; Lei MML; Leung RWH; Tong M; Keng VW; Ma C; Zhao Q; Ng IOL; Ma S; Lee TK
Cancer Res; 2021 Jun; 81(12):3229-3240. PubMed ID: 33903122
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular Carcinoma and Nuclear Paraspeckles: Induction in Chemoresistance and Prediction for Poor Survival.
Kessler SM; Hosseini K; Hussein UK; Kim KM; List M; Schultheiß CS; Schulz MH; Laggai S; Jang KY; Kiemer AK
Cell Physiol Biochem; 2019; 52(4):787-801. PubMed ID: 30946555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
